UC Asset, LP (UCASU)

OTCMKTS · Delayed Price · Currency is USD
1.125
0.00 (0.00%)
Jul 30, 2025, 8:00 PM EDT

Inozyme Pharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2019
Period Ending
Jul '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2019
6437117
Upgrade
Market Cap Growth
43.59%43.59%-60.69%-38.00%54.50%-
Upgrade
Enterprise Value
7546106
Upgrade
Last Close Price
1.130.700.491.242.001.26
Upgrade
PE Ratio
46.6029.0025.68-16.36500.92
Upgrade
Forward PE
-99.2099.2099.20--
Upgrade
PS Ratio
12.027.481.4755.443.131.57
Upgrade
PB Ratio
1.060.660.471.361.550.80
Upgrade
P/TBV Ratio
1.180.740.531.361.620.82
Upgrade
P/FCF Ratio
--12.94---
Upgrade
P/OCF Ratio
--12.94---
Upgrade
EV/Sales Ratio
13.319.072.2152.612.831.42
Upgrade
EV/EBITDA Ratio
--41.63-12.97-
Upgrade
EV/EBIT Ratio
--42.00-14.65-
Upgrade
EV/FCF Ratio
--19.37---
Upgrade
Debt / Equity Ratio
0.010.010.010.120.06-
Upgrade
Debt / EBITDA Ratio
--0.54-0.52-
Upgrade
Debt / FCF Ratio
--0.25---
Upgrade
Asset Turnover
0.090.090.320.020.430.51
Upgrade
Inventory Turnover
--1.360.60--
Upgrade
Quick Ratio
0.210.210.063.961735.0731.49
Upgrade
Current Ratio
10.5810.5812.8915.703848.9831.49
Upgrade
Return on Equity (ROE)
2.30%2.30%1.95%-20.63%8.38%0.16%
Upgrade
Return on Assets (ROA)
-0.81%-0.81%1.05%-11.24%5.16%-3.15%
Upgrade
Return on Capital (ROIC)
-0.82%-0.82%1.05%-11.24%5.17%-3.17%
Upgrade
Return on Capital Employed (ROCE)
--1.70%-9.10%-
Upgrade
Earnings Yield
2.15%3.45%3.89%-18.30%6.11%0.20%
Upgrade
FCF Yield
--0.35%7.73%-9.38%-0.32%-5.08%
Upgrade
Buyback Yield / Dilution
---2.08%0.60%-
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.